Navigation Links
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
Date:10/2/2007

looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended June 30, 2007, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals, Ibis Biosciences and Ibis T5000 are registered trademarks or trademarks of Isis Pharmaceuticals, Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
4. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
5. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Hologic, Inc. (NASDAQ: ... to release its financial results for the third quarter ... the market closes.  In conjunction with the release, management ... p.m. Eastern Time. Interested participants may listen ... the United States ) or 719-325-4804 (for international ...
(Date:7/6/2015)... 2015 E-QURE Corp (OTCQB: EQUR), today announced that ... VirtualInvestorConferences.com on July 9, 2015. DATE: Thursday, July ... This will be a live, interactive ... company questions in real-time - both in the presentation ... If attendees are not able to join the event ...
(Date:7/6/2015)... and FARMINGTON, Conn. ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of Series E warrants to purchase ... F warrants to purchase 2,191,781 shares of its ...
Breaking Medicine Technology:Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
... Weiss, Director of Maryland Laser, Skin and Vein,Institute, ... BALTIMORE, Oct. 2 Robert Weiss, M.D., board ... U.S. to offer his,patients DOT Therapy (Dermal Optical ... Dr. Weiss is an,internationally renowned dermatologist, who is ...
... Biotechnologies AB and Dyax,Corp. (NASDAQ: DYAX ) ... a,collaboration to discover and to develop therapeutic ... inflammatory diseases., The collaboration follows the ... Professors Frostegard and de Faire of the ...
Cached Medicine Technology:DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4
(Date:7/6/2015)... ... July 06, 2015 , ... Acara Partners, a leading business ... of its complimentary educational webinar series for the summer of 2015. ... for their clients through targeted marketing, sales, digital communications, branding and business development ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce that ... Award on behalf of the department of Family Practice. , “This award is a ... practicing in. The technology is changing so rapidly and we are also developing new ...
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer Hope Network ... caregivers and medical professionals to chat with the CHN patient services team and ... a cancer diagnosis is often the most traumatic experience of a person’s life,” ...
(Date:7/6/2015)... , ... July 06, 2015 , ... MD Now, the ... July 6. The newly constructed urgent care center will serve residents and visitors in ... addition to being MD Now’s 22nd South Florida location, the new facility will be ...
(Date:7/6/2015)... ... ... World renowned Los Angeles facial plastic surgeon , Dr. Paul Nassif, ... solutions. Individuals that want to make multiple changes to their facial appearance are able ... of their needs. , "Anytime I see an opportunity to change the life ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... significant bone mass in the first year after the transplant, ... bodies from rejecting the new organ. The bone loss greatly ... fractures among this group ranges from 22 percent to 44 ... but which drugs work best in this situation is unclear. ...
... suggest that kids who struggle to breathe during sleep ... out. ,Adenotonsillectomy is a common surgical procedure in ... performed to treat recurring bouts of tonsillitis. During the ... to treat obstructive sleep apnea (OSA), a condition in ...
... 34 years old. Advances in chemotherapy and radiotherapy have ... cancer, but since men who get the disease are ... and its treatment on fertility remains. ,While ... found fertility rates unchanged. These conflicting results suggested the ...
... has shown that a chemotherapy regimen combining vinorelbine (Navelbine) ... in the treatment of hormone-refractory prostate cancer . Specialists ... earlier in their disease. , However researchers ... treatment regimen is planned. From a group of 66 ...
... failure is a chronic but deadly condition caused by the ... weaker and weaker. An estimated 5 million Americans ... five years. It can be caused by high blood pressure, ... In a recent study it was seen that heart failure ...
... Previous studies show conflicting results over whether hormone replacement ... A recent study examines the pros and cons of ... combined HRT therapy for five years. All the women ... had menopausal symptoms, while others did not.Results show women ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
... BX620S. Digital stability control, analog display ... counting and percent measure functions, auto ... and time data from built-in clock. ... (selectable from 200g to 600g). Built-in ...
The EK-H Series offer 10 selectable units of measure...
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
The EK-H Series offer 10 selectable units of measure...
Medicine Products: